Royalty Pharma plc reported its fourth quarter (Q4) and full year (FY) 2025 results. For Q4 2025, net income attributable to shareholders was USD 214 million. For the full year 2025, net income attributable to shareholders reached USD 771 million. As of December 31, 2025, the company reported cash and cash equivalents of USD 619 million, and total current and non-current financial royalty assets, net, of USD 17.06 billion. Royalty Pharma, founded in 1996, remains the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with a broad range of partners from academic institutions to global pharmaceutical companies. The company emphasized its continued role in supporting innovation in the sector. A replay of the earnings conference call and webcast is available on the company’s website for at least 30 days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652780-en) on February 11, 2026, and is solely responsible for the information contained therein.